Compare DELL & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | GSK |
|---|---|---|
| Founded | 1984 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.7B | 96.1B |
| IPO Year | 2013 | N/A |
| Metric | DELL | GSK |
|---|---|---|
| Price | $124.36 | $59.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $162.13 | N/A |
| AVG Volume (30 Days) | ★ 6.7M | 6.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.70% | ★ 2.94% |
| EPS Growth | N/A | N/A |
| EPS | ★ 5.34 | N/A |
| Revenue | ★ $95,567,000,000.00 | N/A |
| Revenue This Year | $19.33 | $6.75 |
| Revenue Next Year | $11.74 | $4.88 |
| P/E Ratio | ★ $23.15 | $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $66.25 | $32.38 |
| 52 Week High | $168.08 | $61.70 |
| Indicator | DELL | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 67.84 |
| Support Level | $123.05 | $47.89 |
| Resistance Level | $128.41 | $60.37 |
| Average True Range (ATR) | 5.56 | 0.90 |
| MACD | 0.65 | -0.14 |
| Stochastic Oscillator | 71.26 | 53.22 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three market shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.